Nature Communications (Feb 2021)

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

  • Bradley A. Maron,
  • Rui-Sheng Wang,
  • Sergei Shevtsov,
  • Stavros G. Drakos,
  • Elena Arons,
  • Omar Wever-Pinzon,
  • Gordon S. Huggins,
  • Andriy O. Samokhin,
  • William M. Oldham,
  • Yasmine Aguib,
  • Magdi H. Yacoub,
  • Ethan J. Rowin,
  • Barry J. Maron,
  • Martin S. Maron,
  • Joseph Loscalzo

DOI
https://doi.org/10.1038/s41467-021-21146-y
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients. Here, myectomy tissue from patients with obstructive hypertrophic cardiomyopathy and heart failure is analyzed using RNA-Seq, and the results are used to develop individualized protein-protein interaction networks. From this approach, hypertrophic cardiomyopathy is distinguished from dilated cardiomyopathy based on the protein-protein interaction network pattern. Within the hypertrophic cardiomyopathy cohort, the patient-specific networks are variable in complexity, and enriched for 30 endophenotypes. The cardiac Janus kinase 2-Signal Transducer and Activator of Transcription 3-collagen 4A2 (JAK2-STAT3-COL4A2) expression profile informed by the networks was able to discriminate two hypertrophic cardiomyopathy patients with extreme fibrosis phenotypes. Patient-specific network features also associate with other important hypertrophic cardiomyopathy clinical phenotypes. These proof-of-concept findings introduce personalized protein-protein interaction networks (reticulotypes) for characterizing patient-specific pathobiology, thereby offering a direct strategy for advancing precision medicine.